Jaguar animal health seeks mums designation from fda for canalevia (crofelemer) for treatment of exercise-induced diarrhea (eid) in dogs

In december of 2021, fda conditionally approved canalevia™-ca1 for treatment of chemotherapy-induced diarrhea in dogs, and the company expects canalevia could receive fda conditional approval, under the name canalevia™-ca2, for treatment of eid in dogs san francisco, ca / accesswire / february 16, 2022 / jaguar health, inc. (nasdaq:jagx), under its jaguar animal health tradename for the veterinary market, today announced that it has submitted a request to the u.s. food and drug administration's center for veterinary medicine for minor use/minor species (mums) designation for the company's oral plant-based drug candidate canalevia™ (crofelemer) for treatment of exercise-induced diarrhea (eid) in dogs. "mums designation is a status similar to ‘orphan drug' status for human drugs, and it makes the proposed intended use of a mums drug eligible for specific incentives supporting product approval or conditional approval.
JAGX Ratings Summary
JAGX Quant Ranking